loading
Kalvista Pharmaceuticals Inc stock is traded at $12.70, with a volume of 19,042. It is down -2.25% in the last 24 hours and up +0.72% over the past month.
See More
Previous Close:
$12.88
Open:
$12.9
24h Volume:
19,042
Relative Volume:
0.04
Market Cap:
$594.10M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-3.4417
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
+4.92%
1M Performance:
+0.72%
6M Performance:
+7.79%
1Y Performance:
+20.02%
1-Day Range:
Value
$12.54
$12.90
1-Week Range:
Value
$11.77
$13.12
52-Week Range:
Value
$7.30
$15.50

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Name
Name
Kalvista Pharmaceuticals Inc
Name
Phone
(857) 999-0075
Name
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Employee
0
Name
Twitter
@kalvista
Name
Next Earnings Date
2025-03-12
Name
Latest SEC Filings
Name
KALV's Discussions on Twitter

Compare KALV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KALV
Kalvista Pharmaceuticals Inc
12.71 594.10M 0 -156.39M -123.06M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
486.18 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.40 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.79 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.26 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
247.76 24.89B 3.81B -644.79M -669.77M -6.24

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-31-25 Initiated JMP Securities Mkt Outperform
Jan-07-25 Initiated TD Cowen Buy
Dec-18-24 Initiated BofA Securities Buy
Jun-15-20 Initiated H.C. Wainwright Buy
Jul-29-19 Initiated SVB Leerink Outperform
Mar-20-19 Initiated Needham Buy
Oct-30-18 Initiated Jefferies Buy
Sep-21-18 Initiated Cantor Fitzgerald Overweight
Aug-31-17 Initiated BTIG Research Buy
View All

Kalvista Pharmaceuticals Inc Stock (KALV) Latest News

pulisher
03:40 AM

Geode Capital Management LLC Sells 8,632 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

03:40 AM
pulisher
Apr 23, 2025

Kalvista stock holds $19 target, Market Outperform rating - Investing.com

Apr 23, 2025
pulisher
Apr 23, 2025

Kalvista stock holds $19 target, Market Outperform rating By Investing.com - Investing.com India

Apr 23, 2025
pulisher
Apr 22, 2025

Russell Investments Group Ltd. Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Apr 22, 2025
pulisher
Apr 19, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform - insights.citeline.com

Apr 18, 2025
pulisher
Apr 17, 2025

(KALV) Trading Report - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 17, 2025

Vanguard Group Inc. Acquires 104,716 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Apr 17, 2025
pulisher
Apr 15, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by American Century Companies Inc. - Defense World

Apr 15, 2025
pulisher
Apr 15, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc. - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Wellington Management Group LLP Has $1.04 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

KalVista Pharmaceuticals’ Licensing Agreement with Kaken Pharmaceutical - Global Legal Chronicle

Apr 13, 2025
pulisher
Apr 13, 2025

The week in pharma: action, reaction and insight – week to April 11 - The Pharma Letter

Apr 13, 2025
pulisher
Apr 12, 2025

KalVista: Poised For Rare Disease Transformation - Seeking Alpha

Apr 12, 2025
pulisher
Apr 10, 2025

Kaken, Kalvista partner on HAE treatment sebetralstat in Japan - Angioedema News

Apr 10, 2025
pulisher
Apr 09, 2025

KalVista licensing deal with Kaken - The Pharma Letter

Apr 09, 2025
pulisher
Apr 08, 2025

KalVista inks Japan licensing deal for HAE drug sebetralstat - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista inks Japan licensing deal for HAE drug sebetralstat By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista licenses commercialisation rights for HAE to Kaken in Japan - Yahoo

Apr 08, 2025
pulisher
Apr 08, 2025

Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Pharmaceuticals Signs Agreement with Kaken Pharmaceutical - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - BioSpace

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista stock rises on licensing deal in Japan (KALV:NASDAQ) - Seeking Alpha

Apr 08, 2025
pulisher
Apr 08, 2025

Kalvista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical To Commercialize Sebetralstat For HAE In Japan - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

KalVista Pharmaceuticals, Inc. Enters into Licensing Agreement with Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - marketscreener.com

Apr 08, 2025
pulisher
Apr 05, 2025

Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com

Apr 04, 2025
pulisher
Apr 03, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace

Apr 03, 2025
pulisher
Apr 01, 2025

Where are the Opportunities in (KALV) - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Mar 31, 2025

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph

Mar 31, 2025
pulisher
Mar 31, 2025

Charles Schwab Investment Management Inc. Sells 10,372 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Mar 31, 2025
pulisher
Mar 29, 2025

Q4 Earnings Estimate for KALV Issued By Leerink Partnrs - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Earns Buy Rating from Needham & Company LLC - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

KONFIDENT-KID trial of sebetralstat is now fully enrolled - Angioedema News

Mar 27, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Buy on Kalvista stock, price target steady at $39 - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Kalvista shares - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Bank of New York Mellon Corp - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Kalvista stock holds as JMP reiterates $19 target - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

KalVista completes enrollment for pediatric HAE trial By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

KalVista completes enrollment for pediatric HAE trial - Investing.com India

Mar 25, 2025

Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.39
price down icon 0.63%
$68.60
price down icon 0.25%
$32.01
price down icon 0.09%
$34.64
price down icon 7.28%
$114.80
price down icon 4.57%
biotechnology ONC
$248.25
price down icon 2.59%
Cap:     |  Volume (24h):